Project description:RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.

| 2005372 | ecrin-mdr-crc

Human gammaherpesvirus 4

Project description:Rapid detection of Epstein-Barr viral genomes from formalin-fixed, paraffin-embedded samples

| PRJDB17571 | ENA

ChIP-seq analysis with an antibody directed against the human H3K27ac protein in Raji cells (Genbank: KF717093.1) prior to and post induction of BZLF1.

Project description:ChIP peaks were identified in both the human and viral genomes (genome assembly GRCh37 (hg19) and Epstein-Barr virus, Human Herpesvirus 4; GenBank accession KF717093.1).

2021-06-22 | E-MTAB-8421 | biostudies-arrayexpress

Human gammaherpesvirus 4

Project description:genome-wide analysis of Epstein-Barr virus (EBV) isolated from EBV-associated gastric carcinoma (EBVaGC)

| PRJNA289293 | ENA